Posts tagged TEAR
TearLab to request NASDAQ hearing over listing

TearLab (NASDAQ:TEAR; TSX:TLB) has received a letter from the Nasdaq listing qualifications staff, indicating that the company failed to regain compliance with the $1 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The company intends to request a hearing before the Nasdaq Hearings Panel, at which it will present its plan to demonstrate compliance with the bid price requirement and request an extension of time within which to do so.

Read More
Roth downgrades TearLab to neutral

Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday.

Analyst Chris Lewis writes that TearLab’s second quarter year-over-year growth of 9% was the lowest since the first quarter of 2012, prompting the company to once again lower its 2016 outlook.

Read More
TearLab prices $17.3-million registered public offering

TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9.

The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one share of common stock.

Read More
TearLab Q1 revenue climbs 25%

First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago.

A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were under the company’s new Flex program and 61 were purchased outside of the U.S.

Read More
TearLab Q4 revenue climbs 28%

Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014.

A net total of 258 TearLab Osmolality Systems were added in the fourth quarter of 2015, of which 200 were under the company’s new Flex program and 66 were purchased outside of the U.S.

Read More
BioLight reports positive TeaRx test results for DES

BioLight Israeli Life Sciences Investments (OTCQX: BLGTY; TASE: BOLT) has completed a second successful U.S. clinical study to assess the effectiveness of its TeaRx multi-assay test in evaluating tears’ components of healthy subjects as well as of patients suffering from dry eye syndrome (DES).

The study, conducted by development partner Ora Inc., enrolled 74 subjects in the U.S. All study subjects were evaluated using a composite of four established benchmark tests for the assessment of DES, used in previous FDA regulatory approval processes for other DES products, to define and distinguish populations of healthy subjects from those with different grades of DES.

Read More